With the ever-widening gap between what is technologically possible and services available, jurisdictions around the world are faced with complex decisions regarding the introduction and expansion of genetic screening programs. A series of literature reviews and consultations with stakeholders and experts led to the development of a decision support guide for genetic screening policy-making. This involved establishing a preliminary list of core criteria synthesized from the growing literature on genetic screening, which was then transformed through a series of consultations into a more elaborate decision guide. Although certain perennial challenges in genetic screening policy-making remain, the decision support guide aims to promote a fair and evidence-informed process that makes explicit the ethical dilemmas often inherent to such policy decisions.

Keywords:
Genetic screening, Health care rationing, Health policy, Public health
1.
Lander ES, Linton LM, Birren B, et al; International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
2.
Venter JC, Adams MD, Meyers EW, et al: The sequence of the human genome. Science 2001;291:1304–1351.
3.
Human Genetics Programme. Statement of the WHO Expert Consultation on New Developments in Human Genetics. Geneva, World Health Organization, 2000.
4.
Bell J: Predicting disease using genomics. Nature 2004;429:453–456.
5.
Khoury M, Burke W, Thomson E, (eds): Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. Oxford, Oxford University Press, 2000.
6.
Khoury M, McCabe L, McCabe E: Population screening in the age of genomic medicine. New Engl J Med 2003;348:50–58.
7.
Council of Regional Networks for Genetic Services (CORN). Guidelines for Clinical Genetic Services for the Public’s Health. 1st ed. Atlanta: Council of Regional Networks for Genetic Services, 1997.
8.
Halliday J, Collins V, Aitken MA, Richards M, Olsson C: Genetics and public health – evolution or revolution? J Epidemiol Community Health 2004;58:894–899.
9.
Ojha R, Thertulien R: Health care policy issues as a result of the genetic revolution: implications for public health. Am J Public Health 2005;95:385–388.
10.
Bailey D, Skinner D, Warren S: Newborn screening for developmental disabilities: reframing presumptive benefit. Am J Public Health 2005;95:1889–1893.
11.
Pollitt R: International perspectives on newborn screening. J Inherit Metab Dis 2006;29:390–396.
12.
Grosse S, Boyle C, Botkin J, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond B: Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53(RR13):1–36.
13.
Kaufert P: Health policy and the new genetics. Soc Sci Med 2000;51:821–829.
14.
Knoppers B, Hirtle M, Glass K: Commercialization of genetic research and public policy. Science 1999;286:2277–2278.
15.
Leib J, Gollust S, Hull S, Wilfond B: Carrier screening panels for Ashkenazi Jews: Is more better? Genet Med 2005;7:185–190.
16.
Gray JA: Evidence based policy making. BMJ 2004;329:988–989.
17.
McDonald M: Biotechnology, ethics and government: a synthesis. Prepared for The Canadian Biotechnology Advisory Committee, Project Steering Committee on Incorporating Social and Ethical Considerations into Biotechnology. Ottawa, CBAC, 2000.
18.
Caulfield T: Underwhelmed: hyperbole, regulatory policy and the genetic revolution. McGill Law J 2000;45:437–460.
19.
Knoppers B: Reflections: the challenge of biotechnology and public policy. McGill Law J 2000;45:559–566.
20.
Banta H: Considerations in defining evidence for public health. Int J Technol Assess 2003;19:559–572.
21.
Lin V, Gibson B (eds): Evidence-Based Health Policy: Problems and Possibilities. Melbourne, Oxford University Press, 2003.
22.
Dobrow M, Goel V, Lemieux-Charles L, Black N: The impact of context on evidence utilization: a framework for expert groups developing health policy recommendations. Soc Sci Med 2006;63:1811–1824.
23.
Wilson JMG, Jungner G: Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968. Available at http://whqlibdoc.who.int/php/WHO_PHP_34.pdf.
24.
Andermann A, Blancquaert I, Beauchamp S, Dery V: Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the last 40 years. Bull World Health Organ 2008;86:317–319.
25.
National Research Council: Genetic screening: programs, principles, and research. Report of the Committee for the Study of Inborn Errors of Metabolism, Division of Medical Sciences, Assembly of Life Sciences. Washington, DC, National Academy of Sciences, 1975.
26.
Knoppers BM, Laberge CM (eds): Genetic Screening: From Newborns to DNA Typing. Amsterdam, Elsevier Science Publishers, 1990.
27.
American Academy of Pediatrics Newborn Screening Task Force: Newborn screening: a blueprint for the future, a call for a national agenda on state newborn screening programs. Pediatrics 2000;106:S389–S427.
28.
National Screening Committee: Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. London, National Health Service, 2003.
29.
Andermann A, Beauchamp S, Costea I, Blancquaert I: Guiding decision-making for population-based screening: a systematic and multi-dimensional approach applicable to genetics. Montréal: Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS), unpublished data.
30.
Andermann A, Blancquaert I, Déry V: Genetic screening: a conceptual framework for programs and policy making. J Health Serv Res Policy, in press.
31.
Blancquaert I, Beauchamp S, Andermann A: Decision support guide for population based genetic screening. Available at http://www.cangenetest.org/en/publications.html.
32.
The President’s Council on Bioethics: The Changing Moral Focus of Newborn Screening: An Ethical Analysis by the President’s Council on Bioethics. Washington, DC, The President’s Council on Bioethics, 2008.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.